在永磁体领域，公司通过高性能磁性材料及高效磁路设计，并引入低涡流、高开放性等设计技术，可提 供丰富的高质量永磁体，目前是全球规模最大的MRI设备永磁体供应商，产品凭借经济性高、检查舒适 度高、低维护需求等优势，为基层医疗系统普及MRI设备提供有力支撑。截至2025年6月30日，公司已 拥有授权专利85项，其中发明专利45项，先后入选国家专精特新"小巨人"企业、国家专精特新重点"小 巨人"企业，技术实力获认可。 中证报中证网讯(王珞)近日，上交所官网显示，宁波健信超导科技股份有限公司(简称"健信超导")科创 板IPO将于10月21日上会。作为全球领先的医用磁共振成像(MRI)设备核心部件供应商，健信超导此次 冲击科创板，不仅是企业发展的重要里程碑，更将为我国高端医疗装备国产化进程注入新动能。 健信超导深耕MRI核心部件领域多年，以"让磁共振成为老百姓用得起的日常诊查手段"为使命，专注于 超导磁体、永磁体和梯度线圈的研发、生产与销售。这些核心部件占MRI设备核心部件成本的50%左 右，其技术水平直接决定MRI设备的性能与成本，对推动磁共振技术迭代进步及普及具有关键意义。 在超导领域，健信超导已构建起领先的核心技术 ...

本报讯(记者邬霁霞见习记者王楠)近日，上海证券交易所官网披露，宁波健信超导科技股份有限公司(以 下简称"健信超导")将于10月21日接受上市审核委员会审议。 招股说明书显示，健信超导本次募集资金将投资于年产600套无液氦超导磁体项目、年产600套高场强医 用超导磁体技改项目、新型超导磁体研发项目。本次募集资金将围绕该公司的主营业务展开，聚焦国家 战略和重大需求，进一步加大研发创新投入，进一步完善产业链和产品结构，增强公司产品和技术的竞 争力。目前，健信超导已掌握下一代无液氦超导磁体研发生产的核心技术并成功研制出国际首台1.5T无 液氦超导磁体及1.5T大孔径无液氦超导磁体。 公司相关负责人表示，健信超导此次冲刺科创板，不仅是企业自身发展的"里程碑"，更是我国高端医疗 装备核心技术突围的"缩影"。公司以技术创新为核心、产业化为支撑，从零挥发超导到无液氦技术再到 永磁体业务，持续构建研发、生产、市场一体化竞争优势。随着募投项目落地，公司将完善"技术—产 能—市场"闭环，巩固MRI核心部件领先地位，拓展超导应用边界，推动国产替代深入发展，并为高端 医疗装备自主可控与投资者长期价值创造贡献力量。 招股说明书显示，健信 ...

Core Viewpoint - The laparoscopic surgical robot developed by Weijing Medical has officially entered mass production, marking a significant advancement in China's medical robotics industry, which has been rapidly evolving due to supportive policies and capital investments [3][8]. Group 1: Laparoscopic Surgical Robots - Laparoscopic surgical robots are intelligent medical devices designed for minimally invasive surgeries, enhancing precision, reducing tremors, and providing a 10-15 times magnified 3D view, which significantly lowers patient blood loss and recovery time [4][5]. - The core advantages of laparoscopic surgical robots include superior precision control, immersive surgical visualization, and ergonomic operation, which collectively redefine surgical standards [4][5]. - Compared to traditional open and laparoscopic surgeries, robotic systems offer higher precision, greater flexibility, improved visualization, and reduced operator fatigue, leading to better clinical outcomes for patients [7]. Group 2: Commercialization Progress - The global laparoscopic surgical robot market has been historically dominated by Intuitive Surgical's da Vinci system, which has undergone several upgrades since its FDA approval in 2000, with the latest version (dV5) showing significant technological advancements [9][10]. - The da Vinci system's business model, which combines equipment sales with high-margin consumables and services, has created a strong competitive moat, ensuring long-term revenue stability [10]. - In China, the market for laparoscopic surgical robots is experiencing rapid growth, with domestic companies successfully launching products and capturing market share previously held by foreign brands [11][12]. Group 3: Capital Dynamics - The investment landscape for laparoscopic surgical robots in China is shifting from an early-stage boom to a more rational phase, with capital increasingly favoring companies that have demonstrated successful product approvals and clinical usage [14]. - Recent financing activities indicate a slowdown in investment heat, with a focus on companies that have proven their commercialization potential and have established hospital installations [14][16].